SEC 13F Intelligence

Altium Capital Management LLC / XENE

Altium Capital Management LLC’s Xenon Pharmaceuticals Inc Position

Does Altium Capital Management LLC own Xenon Pharmaceuticals Inc (XENE)? Not currently — the last reported position was 60.3K shares worth $2M in Q1 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$2M
Q1 2025
Shares
60.3K
% of Portfolio
+4.87%
Quarters Held
10
position exited

Position History XENE

Reported value by quarter
Q2 ’21: $3MQ2 ’21Q3 ’21: $3MQ2 ’23: $9MQ2 ’23Q3 ’23: $8MQ4 ’23: $13MQ4 ’23Q1 ’24: $15MQ2 ’24: $14MQ2 ’24Q3 ’24: $14MQ4 ’24: $11MQ4 ’24Q1 ’25: $2Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202560.3K$2M+4.87%
Q4 2024288.0K$11M+3.20%
Q3 2024360.6K$14M+4.18%
Q2 2024360.6K$14M+5.74%
Q1 2024348.0K$15M+5.93%
Q4 2023290.5K$13M+9.08%
Q3 2023228.0K$8M+4.06%
Q2 2023228.0K$9M+6.64%
Q3 2021216.0K$3M+0.87%
Q2 2021155.0K$3M+0.67%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Altium Capital Management LLC’s full portfolio or all institutional holders of XENE.